Lung Cancer最新文献

{"title":"Serum mesothelin as a response biomarker in pleural mesothelioma","authors":"Geraldine A. Lynch ,&nbsp;Jenny Symonds ,&nbsp;Anna Morley ,&nbsp;Emeka Azubuike-Dyer ,&nbsp;Will Cooper ,&nbsp;Anthony Edey ,&nbsp;Duneesha De Fonseka ,&nbsp;Selina Tsim ,&nbsp;Kevin Blyth ,&nbsp;Paul White ,&nbsp;Nick A. Maskell ,&nbsp;Anna Bibby ,&nbsp;on behalf of the ASSESS-meso Collaborative group","doi":"10.1016/j.lungcan.2025.108670","DOIUrl":"10.1016/j.lungcan.2025.108670","url":null,"abstract":"<div><h3>Background</h3><div>CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST criteria. While mRECIST has its own challenges, attending for CT scans adds time and expense. A blood-based biomarker which tracks disease status could enable more responsive, community-based disease monitoring. This study evaluated the relationship between serial serum mesothelin (SM) levels and disease status.</div></div><div><h3>Methods</h3><div>Patients with PM were recruited from Assess-Meso, a multi-centre prospective cohort study of patients with mesothelioma, between 28/2/2019 and 31/12/2023. Logistic regression, adjusted for sex, age, histology, performance status, eGFR and treatment, was used to assess the relationship between serial SM and radiological disease status. Prespecified sub-group analyses stratified participants by initial SM and treatment status.</div></div><div><h3>Results</h3><div>156 patients had ≥ 2 SM measurements with paired CT scans. Rising SM was associated with disease progression in the coincident time period (Adj OR 1.11, 95 % CI 1.03–1.19) and the subsequent 6 months (Adj OR 1.13, 1.03–1.23), regardless of initial SM. A 25 % change in SM was the optimal threshold, with a 25 % rise associated with disease progression (Adj OR 2.68 (1.52–4.73)) with sensitivity and specificity of 48.7 % (43.1 %-54.4 %) and 75.7 % (70.8 %-80.5 %) respectively. For patients receiving treatment, falling SM predicted subsequent disease response (Adj OR 1.37, 1.16–1.61).</div></div><div><h3>Conclusions</h3><div>Serial SM is a reliable response biomarker in PM, regardless of initial value and treatment status. These results support the use of SM in routine clinical care as an adjunct to CT scans, with several benefits over radiological monitoring.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108670"},"PeriodicalIF":4.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy","authors":"Danrong Zhong ,&nbsp;Grigory Sidorenkov ,&nbsp;Keris Poelhekken ,&nbsp;Yihui Du ,&nbsp;Karin M. Vermeulen ,&nbsp;Rozemarijn Vliegenthart ,&nbsp;Marjolein A. Heuvelmans ,&nbsp;Harry J.M. Groen ,&nbsp;Marcel J.W. Greuter ,&nbsp;Geertruida H. de Bock","doi":"10.1016/j.lungcan.2025.108669","DOIUrl":"10.1016/j.lungcan.2025.108669","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer screening in high-risk populations with low-dose computed tomography (LDCT) reduces lung cancer mortality by detecting cancer at early stage. Immunotherapy improves survival in these patients. This study evaluates the cost-effectiveness and budget impact of LDCT screening extending immunotherapy to early-stage patients.</div></div><div><h3>Methods</h3><div>A micro-simulation model Simulation Model on Radiation Risk and cancer Screening (SiMRiSc, validated against NELSON results) was used to a Dutch heavy smokers cohort. Average cost-effectiveness ratio (ACER), lung cancer mortality reduction, and budget impact of biennial screening for heavy smokers aged 55–74 (adapted from the UK strategy) were evaluated in context of immunotherapy, compared with no-screening. A cost-effectiveness threshold was set at 60 k€ per life year gained (LYG).</div></div><div><h3>Results</h3><div>Compared with no-screening, limiting immunotherapy to advanced-stage patients, screening resulted in ACERs of 4.7 k€/LYG for males and 6.6 k€/LYG for females, reducing lung cancer mortality by 18.1 % and 17.1 %, respectively. Extending immunotherapy to all stages increased ACERs to 5.2 k€/LYG for males and 7.1 k€/LYG for females, with lung cancer mortality reduction of 21.1 % and 20.1 %, respectively. Budget impact analysis shows screening saved 35–52 million€ when immunotherapy restricted to advanced-stage, and 24–39 million€ for all stages immunotherapy over three-screening rounds compared with no-screening, primarily due to a 53 % reduction for advanced-stage cases.</div></div><div><h3>Conclusion</h3><div>Lung cancer screening in high-risk population remains cost-effective when immunotherapy is offered to all stages. By shifting diagnoses from advanced to early stages, screening yielding substantial savings. These findings support LDCT screening implementation even in healthcare systems broadly using immunotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108669"},"PeriodicalIF":4.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet","authors":"Astrid Paulus ,&nbsp;Marius Zemaitis ,&nbsp;Saulius Cicenas ,&nbsp;Zanete Zvirbule ,&nbsp;Annika Sanfridson ,&nbsp;Camilla Rydberg Millrud ,&nbsp;Susanne Magnusson ,&nbsp;Nedjad Losic ,&nbsp;Dominique Tersago ,&nbsp;Ignacio Garcia-Ribas ,&nbsp;Lars Thorsson ,&nbsp;Luis G. Paz-Ares","doi":"10.1016/j.lungcan.2025.108664","DOIUrl":"10.1016/j.lungcan.2025.108664","url":null,"abstract":"<div><h3>Introduction</h3><div>Interleukin-1 receptor accessory protein (IL1RAP), expressed in several tumors, is essential for IL-1α and IL-1β signaling which leads to tumor progression and treatment resistance. Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling. Efficacy and safety of nadunolimab plus platinum-based doublet chemotherapies were assessed in patients with non-small cell lung cancer (NSCLC) (NCT03267316).</div></div><div><h3>Methods</h3><div>Patients with advanced NSCLC received nadunolimab plus platinum-based doublet chemotherapies in first-line or second-line post-pembrolizumab. Study objectives included the anti-tumor response, progression-free survival (PFS), overall survival (OS), levels of biomarkers in serum, and immunohistochemistry of baseline and on-treatment tumor biopsies.</div></div><div><h3>Results</h3><div>43 patients were enrolled, median age 64 years, 38 % female, and 43 % were treated in second-line post-pembrolizumab. Median PFS was 7.2 months (95 % CI 5.6–9.2), median OS was 13.7 months (95 % CI 11.1–18.3), and 1-year survival was 54 %. The greatest benefits were observed in 11 patients with non-squamous histology treated in second-line post-pembrolizumab: median OS 26.7 months, ORR 91 % including two complete responders (with distinct biomarker profiles), and 1-year survival 82 %. Biomarker analyses showed that patients in second-line post-pembrolizumab had an enhanced level of tumor-infiltrating immune cells compared to treatment naïve patients. Rates of Grade 3+ neutropenia, anemia, and thrombocytopenia were higher than previous reports of platinum-based doublet chemotherapies alone.</div></div><div><h3>Conclusions</h3><div>Nadunolimab plus platinum-based doublet chemotherapies showed promising efficacy in advanced NSCLC, with the greatest benefit in patients with non-squamous histology treated in second line after relapsing on pembrolizumab treatment.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108664"},"PeriodicalIF":4.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts","authors":"Nancee Pronsati ,&nbsp;Geoffrey Liu ,&nbsp;Todd M. Bauer ,&nbsp;Enriqueta Felip ,&nbsp;Yasushi Goto ,&nbsp;Gerald Green ,&nbsp;Mary Grizzard ,&nbsp;Michael Hamel ,&nbsp;Julien Mazieres ,&nbsp;Tony Mok ,&nbsp;Stephanie Snow ,&nbsp;Benjamin J. Solomon ,&nbsp;Jan Stratmann ,&nbsp;Ken Culver","doi":"10.1016/j.lungcan.2025.108662","DOIUrl":"10.1016/j.lungcan.2025.108662","url":null,"abstract":"<div><div>Lorlatinib is an oral treatment for patients with advanced <em>ALK</em>-positive non-small cell lung cancer (NSCLC). Its efficacy was demonstrated in the CROWN clinical study, in which data from 5 years of follow-up demonstrated effective long-term disease control in patients with advanced <em>ALK</em>-positive NSCLC. While lorlatinib has a distinct side effect profile, its side effects are generally manageable. Managing side effects successfully is critical to preserving patient quality of life and promoting adherence to treatment—both of which are key to maximizing the long-term benefits of lorlatinib. The CROWN study showed that lorlatinib-associated side effects can be managed with dose adjustments, such as lowering the daily dose, without sacrificing treatment effectiveness. This guide, developed collaboratively by patients living with advanced <em>ALK</em>-positive NSCLC and healthcare professionals experienced with managing lorlatinib treatment, aims to help patients understand what to expect from treatment and how to take an informed, active role in their care.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108662"},"PeriodicalIF":4.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An introduction to pragmatic trials in lung cancer research: A multi-faceted approach","authors":"Sarah Bowen Jones ,&nbsp;Gareth Price ,&nbsp;Corinne Faivre-Finn","doi":"10.1016/j.lungcan.2025.108663","DOIUrl":"10.1016/j.lungcan.2025.108663","url":null,"abstract":"<div><div>Pragmatic clinical trials (PTs) are increasingly recognised as a key methodology in lung cancer research, designed to evaluate the effectiveness of interventions in routine clinical settings. In contrast to traditional randomised controlled trials (RCTs), which involve highly selected patient populations under ideal conditions, PTs enrol broader, more representative cohorts, use streamlined trial procedures, and focus on outcomes that reflect patient-centred priorities. This enhances the generalisability of the results and supports evidence-based, joint decision-making between patients and clinicians. PTs offer a more sustainable and scalable path to generate clinically meaningful evidence that improves the quality of patient care and can address longstanding evidence gaps in the management of patients with lung cancer.</div><div>This narrative review outlines the main features of PTs, highlighting the PRECIS-2 tool as a framework to design and evaluate the degree of pragmatism of a trial. Common challenges in clinical trial design — including recruitment of participants, informed consent, selection of appropriate clinical endpoints, data quality — are discussed alongside practical solutions. The emerging role of PTs in generating regulatory-grade evidence and the impact of PTs on clinical guidelines is discussed. Ongoing PTs are outlined, which demonstrate how pragmatic methodologies can be used to the evaluate screening interventions, therapeutic strategies and models of care delivery across a range of clinical settings.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108663"},"PeriodicalIF":4.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States","authors":"Ian Nykaza ,&nbsp;Anjile An ,&nbsp;Jonathan Villena-Vargas ,&nbsp;Lauren Mount ,&nbsp;Nasser K Altorki ,&nbsp;Rulla M Tamimi","doi":"10.1016/j.lungcan.2025.108661","DOIUrl":"10.1016/j.lungcan.2025.108661","url":null,"abstract":"<div><h3>Background</h3><div>Significant progress has been made in reducing lung cancer mortality in the United States, largely due to decreased smoking rates and advancements in treatment, particularly for non-small cell lung cancer (NSCLC). However, lung cancer remains the leading cause of cancer-related deaths, with an estimated 127,010 deaths in 2023. Disparities persist in lung cancer incidence, screening, and treatment, influenced by factors such as race, ethnicity, socioeconomic status, and geography.</div></div><div><h3>Methods</h3><div>This study analyzed NSCLC treatment patterns in 302,744 patients from the National Cancer Database (NCDB) diagnosed between 2015–2018, focusing on adherence to National Comprehensive Cancer Network (NCCN) guidelines and disparities in immunotherapy receipt.</div></div><div><h3>Results</h3><div>Overall, 62% of patients received guideline-concordant treatment, though this varied significantly by stage, with only 54% of stage IV patients receiving appropriate care. Disparities in guideline adherence were observed, particularly among non-Hispanic Black patients, elderly individuals, and uninsured or Medicaid-covered patients. Additionally, patients at academic institutions and high-volume facilities were more likely to receive concordant treatment, whereas those at community cancer programs and minority-serving hospitals (MSH) had lower adherence rates. Immunotherapy, increasingly recommended since 2017, was also less accessible to non-Hispanic Black, Hispanic, and Asian patients, those without private insurance, elderly individuals, and patients receiving treatment at MSH institutions.</div></div><div><h3>Conclusions</h3><div>These findings highlight the need for targeted interventions to address persistent disparities in lung cancer treatment, present from individual to institutional levels, in order to ensure equitable access to recommended treatments and advanced therapies like immunotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108661"},"PeriodicalIF":4.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of 18F-FDG PET metabolic parameters combined with the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer after surgery","authors":"You Cheng ,&nbsp;Guo-Jian Huang ,&nbsp;Xiao-bo Chen ,&nbsp;Hao-yu Zhu ,&nbsp;Kai-yu Lu ,&nbsp;Fan Yang ,&nbsp;Jia-tao Zhang ,&nbsp;Zai-yi Liu ,&nbsp;Dan Shao","doi":"10.1016/j.lungcan.2025.108660","DOIUrl":"10.1016/j.lungcan.2025.108660","url":null,"abstract":"<div><h3>Objective</h3><div>To study the ability of the combination of ¹⁸F-FDG positron-emission tomography/computed tomography (PET/CT) metabolic parameters and the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer (NSCLC) after surgery.</div></div><div><h3>Methods</h3><div>The clinical data and disease-free survival (DFS) data of 157 NSCLC patients who underwent ¹⁸F-FDG PET/CT at 2 weeks before surgery and were regularly monitored for MRD after surgery were retrospectively analyzed. The correlation between PET metabolic parameters and the dynamic monitoring of MRD and the values of the two in predicting prognosis of NSCLC were analyzed.</div></div><div><h3>Results</h3><div>Survival analysis revealed that patients with elevated ¹⁸F-FDG PET metabolism had a worse prognosis, while MRD-positive patients had a significantly worse prognosis than MRD-negative patients. By combining of PET metabolic parameters and MRD status, the PET-high-metabolism + MRD-positive group had a worse prognosis than the PET-high-metabolism + MRD-negative group or the PET-low-metabolism + MRD-positive group and the PET-low-metabolism + MRD-negative group. The prognostic model established by tumor TNM staging, clinical data and PET metabolic parameters(comd 1 model) had a high predictive value (C-index: 0.759, 95 % CI: 0.683–0.835). After adding this model to the MRD detection results(comd 2 model), the prognostic accuracy of the model improved (C-index: 0.873, 95 % CI: 0.824–0.922).</div></div><div><h3>Conclusion</h3><div>The prognostic model made up of Tumor TNM staging,¹⁸F-FDG PET metabolic parameters and clinical data can accurately predict recurrence in NSCLC patients after surgery. Incorporating the results of the dynamic monitoring of MRD detection into the model can significantly enhance its the prognostic accuracy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108660"},"PeriodicalIF":4.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in lung adenocarcinoma","authors":"Sergey Zolov ,&nbsp;Sergei Chuikov ,&nbsp;Shiva Krishna Katkam ,&nbsp;Peter J. Chockley ,&nbsp;Guoan Chen ,&nbsp;Venkateshwar G. Keshamouni","doi":"10.1016/j.lungcan.2025.108643","DOIUrl":"10.1016/j.lungcan.2025.108643","url":null,"abstract":"<div><div>Advances in targeted therapies, immune-checkpoint inhibitors, and chemo-immunotherapy combinations have improved survival in subsets of lung adenocarcinoma (LUAD) patients, yet novel treatments are needed for those who do not respond. We previously demonstrated that Cell Adhesion Molecule 1 (CADM1) is modulated by EMT-MET cycling in lung cancer cells, and mediates NK-mediated immune surveillance. In this study, CADM1 expression was confirmed on the cell surface, correlating with poor survival in LUAD patients, identifying it as a potential therapeutic target for chimeric antigen receptor (CAR) based approach. An anti-CADM1 chimeric antigen receptor (CAR) was developed, demonstrating robust CADM1-specific activity against lung cancer cells. CADM1-CAR-T cells exhibited a balanced composition of stem cell-like (T_SCM), central memory (T_CM), along with effector memory (T_EM), and effector (T_EFF) T cells, crucial for immediate and sustained tumor eradication. In NSG mouse models with orthotopic LUAD xenografts, CADM1-CAR-T cells inhibited tumor growth and extended survival compared to controls, with no effect on CADM1-negative xenografts. Interestingly, CADM1-CAR-T cells did not inhibit subcutaneous tumor growth but effectively reduced spontaneous metastases, underscoring their potential in metastatic LUAD. These findings establish CADM1 as a new target for CAR-T therapies, highlighting its promise for treating both primary and metastatic LUAD.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108643"},"PeriodicalIF":4.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic modalities for superior sulcus tumor (Pancoast) tumor – A systematic review","authors":"Susan Langer ,&nbsp;Daniel Medenwald ,&nbsp;Dirk Vordermark ,&nbsp;Wolfgang Schuette ,&nbsp;Karl-Matthias Deppermann ,&nbsp;Monika Nothacker ,&nbsp;Stephan Eggeling ,&nbsp;Ljupcho Efremov","doi":"10.1016/j.lungcan.2025.108640","DOIUrl":"10.1016/j.lungcan.2025.108640","url":null,"abstract":"<div><h3>Background</h3><div>Superior sulcus tumors (SST) are usually treated with multimodal therapy, mainly trimodal therapy encompassing radiochemotherapy (CRT) followed by surgery. However, high-level evidence from randomized trials remains limited. We conducted a systematic review to assess the evidence of treatment strategies considering adverse events and oncologic outcomes.</div></div><div><h3>Methods</h3><div>We systematically searched MEDLINE, CINAHL, EMBASE, Web of Science, CENTRAL, grey literature databases, and clinical trial registries. We included prospective and retrospective studies published between 1990 and 2024 with mono-, bi- or trimodal treatment reporting outcomes such as overall survival (OS), progression-free survival (PFS), resection rates, postoperative mortality/morbidity, and adverse events. Studies required histologically confirmed SST and a minimum of 30 patients.</div></div><div><h3>Results</h3><div>Thirty-five studies were included (28 retrospective, 7 prospective), with follow-up ranging from 10 to 107 months. Most studies originated from Europe (n = 16) and North America (n = 14). Sample sizes ranged from 30 to 2910 patients, predominantly male and aged in the late 50s to early 60s. Induction CRT protocols varied widely. R0 resection rates were reported in 33 studies, and trimodal therapy outcomes in 12. Hematotoxicity and esophagitis were the most common adverse events. Five-year OS rates varied between 11.8 % and 77 %, with trimodal therapy associated with better survival and distant metastasis as the dominant recurrence pattern. There were no studies addressing immunotherapy.</div></div><div><h3>Conclusion</h3><div>While trimodal therapy remains the guideline-endorsed standard for SST, comparative evidence remains sparse. The role of immunotherapy in induction regimens warrants further investigation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108640"},"PeriodicalIF":4.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clearing the air: Empowering high-risk adults with digital tools for smoking cessation and lung cancer screening adoption","authors":"Mary E. Cooley ,&nbsp;Sun S. Kim ,&nbsp;Niya Xiong ,&nbsp;Hillary Heiling ,&nbsp;Emanuele Mazzola ,&nbsp;Manan M. Nayak ,&nbsp;Rosanna DeMarco ,&nbsp;Andrea Borondy-Kitts ,&nbsp;Meghan Underhill ,&nbsp;Michael J. Healey ,&nbsp;Chi-Fu Jeffrey Yang ,&nbsp;Christopher Lathan ,&nbsp;Peter J. Castaldi","doi":"10.1016/j.lungcan.2025.108647","DOIUrl":"10.1016/j.lungcan.2025.108647","url":null,"abstract":"<div><h3>Background</h3><div>Even though lung cancer screening decreases mortality, uptake remain low. Research has focused on integrating smoking cessation into lung cancer screening programs rather than providing lung cancer screening education to eligible adults. Engaging individuals who are at high-risk for lung cancer and educating them about lung cancer screening is a critical next step. This study tested efficacy of a digital intervention to improve smoking cessation and lung cancer screening adoption.</div></div><div><h3>Methods</h3><div>Participants (n = 152) were enrolled into a randomized controlled trial of a digital intervention (counseling, nicotine replacement treatment, storytelling videos, and lung cancer screening decision-aide) versus a brief intervention (brief advice for smoking cessation, referral to the Quitline and mailing lung cancer screening decision-aide). Demographic, tobacco, and lung health data were collected electronically. Salivary cotinine test verified 7-day point-prevalence abstinence (PPA) rates were obtained at 3 and 6-months after study entry. Descriptive statistics, Fisher’s exact test, Wilcoxon rank-sum test and logistic regression were used for analyses.</div></div><div><h3>Results</h3><div>As compared to the brief arm, the digital intervention had higher rates of biochemically verified 7-day PPA at 3 (35.1 % vs. 15.4 %, p = 0.006) and 6-months (24.3 % vs.10.3 %, p = 0.03). Participants in the digital arm had higher rates of lung cancer screening adoption at 6-months after study entry (58.1 % vs. 29.5 %, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The digital intervention increased smoking cessation and uptake of lung cancer screening adoption compared to a brief intervention. Testing of the digital intervention among a diverse population is warranted to promote earlier detection and decreased mortality from lung cancer.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108647"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}